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Abstract
Transient receptor potential cation channel, subfamily V, member 6 (TRPV6) is an epithelial Ca2+
channel protein expressed in calcium absorbing organs. In the present study, we investigated the
expression and regulation of uterine and placental TRPV6 during gestation in rodents. Uterine
TRPV6 peaked at pregnancy day (P) 0.5, P5.5 and, P13.5 and was detected in uterine epithelium and
glands of rats, while placental TRPV6 mRNA levels increased in mid-gestation. Uterine and
placental TRPV6 mRNA levels in rats appear to cyclically change during pregnancy, suggesting that
TRPV6 may participate in the implantation process. In addition, uterine TRPV6 mRNA is only
expressed in placenta-unattached areas of the uterus, and uterine TRPV6 immunoreactivity was
observed in luminal and glandular epithelial cells. In the placenta, TRPV6 was detected in the
labyrinth and spongy zone. These results may indicate that TRPV6 has at least two functions:
implantation of the embryo and maintenance of pregnancy. To investigate the pathway(s) mediating
TRPV6 expression in rodents, anti-steroid hormone antagonists were injected prior to maximal
TRPV6 expression. In rats, TRPV6 expression was reduced by RU486 (an anti-progesterone)
through progesterone receptors, and ICI 182,780 (an anti-estrogen) blocked TRPV6 expression via
estrogen receptors in mice. The juxtaposition of uterine and placental TRPV6 expressed in these
tissues supports the notion that TRPV6 participates in transferring calcium ions between the
maternal and fetal compartments. Taken together, TRPV6 gene may function as a key element in
controlling calcium transport in the uterus between the embryo and the placenta during pregnancy.
Background
Uterine calcium ions are considered to be a critical factor
for smooth muscle contraction and embryo implantation.
At the implantation stage, these ions may help in secreting
uterine extra-cellular matrix components at the site of
implantation, and during pregnancy and labor calcium
ions may regulate uterine tension [1,2]. Despite these crit-
ical roles of calcium, the regulation of uterine calcium lev-
els is not yet fully understood. In calcium absorbing
organs, i.e., intestine and kidney which express several cal-
cium processing proteins, the regulation and function of
calcium ions and the associated genes are relatively well
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understood. Calcium ions are processed via entering,
transporting, and extruding proteins [3-5]. The transient
receptor potential cation channel, subfamily V, member
(TRPV) 5 and 6 were found in apical membranes of intes-
tinal and renal epithelial cells, and are proposed as medi-
ators for calcium uptake during trans-cellular transport
[6]. Cytosolic calbindin-D9k and -28 k transport calcium
ions from apical to basolateral layers, and theses ions are
finally extruded from the cell membrane via plasma mem-
brane Ca2+ ATPase and sodium-calcium exchanger 1 [4,5].
In the past decade, uterine calcium-binding proteins have
been studied to elucidate the function of uterine calcium
ions, however their regulation and mechanisms of action
are not completely resolved [7-9].
In female reproductive organs, TRPV6 is expressed in the
uterus as well as in the placenta [10-12]. In calcium
absorbing organs, TRPV6 expression is regulated by vita-
min D, estrogen and dietary calcium. An active form of
vitamin D increases duodenal calcium absorption, and
abnormally low calcium absorption has been observed in
vitamin D receptor-knockout mice [4,13]. Dietary calcium
can also induce duodenal and renal TRPV6 mRNA expres-
sion [5,14], and estrogen therapy in menopausal women
induces duodenal TRPV6 mRNA, suggesting that this hor-
mone independently modulates TRPV6 expression [15].
TRPV6 of the female reproductive organs is robustly
expressed; however its exact role is reproduction is not
clearly understood. In the previous study, we reported
that rat TRPV6 is expressed in the uterine endometrium
and glandular endometrium [11,12] and is up-regulated
at diestrus in matured animals and by progesterone sup-
plementation in immature or ovariectomized animals
[11]. Recently, the physiological significance of TRPV6/
Ca2+ channel in maternal-fetal Ca2+ transport was investi-
gated using TRPV6 knockout mice [16], demonstrating
that Ca2+ concentration in fetal blood and amniotic fluid
was significantly lower and the transport activity of radio-
active Ca2+ from mother to fetuses was 40% lower in
TRPV6 KO fetuses than in WTs. Progesterone appears to
be a dominant regulator of TRPV6 via progesterone recep-
tor activation [11]. In a mouse model, uterine TRPV6
expression varied during estrous cycles, however it was
dominantly observed at the estrous stage [12]. In addi-
tion, estrogen seemed to be a major factor in the regula-
tion of uterine TRPV6 transcription via estrogen receptor
α pathway [12]. However, the role of TRPV6 in the
implantation process during pregnancy is not yet deter-
mined.
Thus, in the present study, we employed a rat model to
examine the expression of TRPV6 mRNA in the uterus and
placenta during pregnancy. In addition, we investigated
whether sex hormones regulate uterine TRPV6 expression
in rats and mice during pregnancy, using antagonists for
estrogen and progesterone. Finally, we further determined
the localization of TRPV6 protein in the uterus and pla-




Sprague-Dawley rats (male, 12-week-old; female, 10-
week-old) and pregnant ICR mice (12 to 15-week-old)
were obtained from KOATECH (Pyeongtaek, Gyeonggi,
Korea). All animals were housed in polycarbonate cages,
and acclimatized to an environmentally controlled room
before experimentation (temperature, 23 ± 2°C; relative
humidity, 50 ± 10%; frequent ventilation and 12 h light
cycle). Experiments were performed with the approval of
the Animal Ethics Committee at the College of Veterinary
Medicine, Chungbuk National University. Adult female
rats were mated with adult males overnight [17], then
examined the following morning for the presence of a vag-
inal plug. This time point was designated as day 0.5 of
pregnancy (P0.5) when the morning a plug is found. The
rats (n = 3 per group) were euthanized on each day of
pregnancy (P0.5 to P21.5).
Pregnant rats (P4.5 for uterine RNA preparation, P19.5 for
placental RNA preparation) received subcutaneous injec-
tions of RU486 (RU, 2.5 mg per rat; Sigma-Aldrich Corp,
St. Louis, MO), ICI 182,780 (ICI, 0.5 mg per rat; Tocris,
Eslisvill, Missouri, USA) or 50% ethanol as a vehicle
[11,18]. In addition, ICR mice at P9.5 were injected with
RU (25 μg per mouse) or ICI (2 μg per mouse) [19]. The
chemicals were dissolved in 0.2 ml ethanol and saline
mixture (1:1), and 0.2 ml and 0.05 ml were administered
to rats and mice, respectively. The pregnant rats were
treated with the antagonists one day before TRPV6 mRNA
is maximally expressed depending on the tissues and spe-
cies [12].
Total RNA extraction and reverse transcriptase (RT)-PCR
Animals were euthanized, and the uteri and placentas
were rapidly excised and washed in cold sterile saline
(0.9% NaCl). Total RNA was prepared with TRIzol reagent
(Invitrogen Life Technologies, Inc., Carlsbad, California,
USA), and the concentration was determined by measur-
ing light absorbance at 260 nm. Before RT-PCR, total RNA
samples were electrophoresed on 1% formaldehyde dena-
turing agarose gels to validate the quality and purity. RT-
PCR was performed, and the resulting products were visu-
alized by agarose gel electrophoresis as described previ-
ously [20]. In brief, total RNA (1 μg) was reverse
transcribed to first strand complementary DNA (cDNA)
using mMLV reverse transcriptase (Invitrogen Life Tech-
nologies, Inc.) and random primers (9 mers; TaKaRa Bio.
Inc., Otsu, Shiga, Japan). TRPV6 and 1A (cytochrome oxi-
dase subunit I, a house keeping gene) were amplified in aReproductive Biology and Endocrinology 2009, 7:49 http://www.rbej.com/content/7/1/49
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20  μl PCR reaction containing 1 U Taq polymerase
(iNtRON Bio Inc, Sungnam, Kyungki-Do, Korea), 1.5 mM
MgCl2, 2 mM dNTP, and 50 pmol TRPV6- or 1A specific
primers [12]. The oligonucleotide sequences for TRPV6
were 5'-GTG CTG GGT GCC ATC TAC GT-3' (sense) and
5'-CAA TGA TGA CAT GGA ATG GCC-3' (antisense). The
primer sequences for 1A were 5'-CCA GGG TTT GGA ATT
ATT TC-3' (sense) and 5'-GAA GAT AAA CCC TAA GGC
TC-3' (antisense). PCR reactions were denatured at 95°C
for 30 s, annealed at 60°C for 30 s and extended at 72°C
for 45 s. TRPV6 and 1A were quantified after 25 and 18
cycles, respectively. PCR products (10 μl) were separated
on a 2% agarose gel, stained with ethidium bromide, and
photographed under UV illumination. Photographs were
taken using a Gel Doc EQ (Bio-Rad, Hercules, California,
USA).
Real-time PCR using TaqMan™ probe
Real-time PCR was performed in 20 μl reactions contain-
ing 10 μl TaqMan Universal PCR Master Mix (Applied
Biosystems, Foster, CA, USA), and 1 μl of 20×Assays-on-
Demand ™ Gene Expression Assay Mix (Applied Biosys-
tems; rat TRPV6, Rn00586673_A1 [Assay ID in the
Applied Biosystmes]; mouse TRPV6, Mm00499069_m1;
rat HPRT1 (hypoxanthine guanine phosphoribosyl trans-
ferase 1, an internal control), Rn01527840_A1; mouse
HPRT1, Mm00446968_m1) and 2 μl cDNA. PCR amplifi-
cation was conducted using a 7300 Real-Time PCR System
(Applied Biosystems), with initial enzyme activation at
50°C for 2 min, followed by 90°C for 10 min. Each of 40
amplification cycles consisted of denaturation at 95°C for
15 sec, followed by annealing and extension at 60°C for 1
min. Relative expression levels for each sample were deter-
mined using RQ software (Applied Biosystems). The
expression of TRPV6 was normalized relative to that of
HPRT1 [21,22]
Immunohistochemistry
The tissue localization of TRPV6 protein was examined by
immunohistochemistry by using Vectastain Universal
Elite ABC Kit (Cat. No. PK-6200, Vacter Laboratories, Inc.,
Burlingame, California, USA) as previously described
[12]. The uterus from P5.5 to P 10.5 and placenta from
P11.5 to P13.5 were embedded in paraffin. Sections (5
μm) were deparaffinized in xylene and hydrated in
descending grades of ethanol. TRPV6 staining involved
immersion of the uterus and placenta sections in boiled
citrate target retrieval buffer (0.01 M sodium citrate and
0.01 M citric acid, pH 6.0) at 100°C for 5 min. Endog-
enous peroxidase activity was blocked with 3% hydrogen
peroxide in PBS-T (PBS containing 0.05% tween20) for 30
min. Incubation of the section in 10% normal goat serum
(NGS) for 2 h at room temperature blocked nonspecific
reaction. Sections were subsequently incubated with a
polyclonal rabbit antibody specific to TRPV6 (#ACC-036,
0.8 mg/ml, diluted 1:100; Alomone Labs Ltd., Jerusalem,
Israel) dissolved in 10% NGS, at room temperature for 2
h. A negative control was incubated with in 10% normal
serum for 2 h at room temperature. After washing with
PBS-T, the sections were incubated with biotinylated sec-
ondary antibody (anti-rabbit IgG; Vector Laboratories,
Inc.) for 30 min at 37°C and further incubated with
FAST™ 3,3'-Diaminobenzidine Tablets (#D4293, Sigma-
Aldrich) for 30 min at 37°C. The sections were counter-
stained with hematoxylin followed by mounting with a
coverslip.
Data analysis
Data were analyzed by nonparametric one-way analysis of
variance using the Kruskal-Wallis test, followed by Dun-
nett's test for multiple comparisons to vehicle. All statisti-
cal analyses were performed with SPSS for Windows
Edition (SPSS, Chicago, Illinois, USA). p < 0.05 was con-
sidered statistically significant.
Results
Expression of TRPV6 mRNA in the uterus and placenta 
during pregnancy
The expression of rat TRPV6 mRNA during pregnancy was
examined by RT- and real-time PCR. The uteri were col-
lected from rats at P0.5 to P21.5, and fetuses were
removed.  TRPV6  mRNA was moderately expressed at
P0.5, decreased through P4.5, and then suddenly
increased to the highest level at P5.5 (Figure 1). Following
Expression of uterine TRPV6 mRNA during pregnancy in rats Figure 1
Expression of uterine TRPV6 mRNA during preg-
nancy in rats. Uteri of gestating rats (n = 2) were collected 
daily from P0.5 to P21.5, and expression of TRPV6 mRNA 
was assayed by RT-PCR (Top panel, agarose gel image) and 
Real-Time PCR (Bottom panel, line graph). The unattached 
uteri containing uterine epithelial cells were used as a RNA 
preparation from P1.3.5. The line graph shows the analysis of 
Real-Time PCR data expressed as a percentage of TRPV6/
HPRT1 (mean ± SEM of duplicates).Reproductive Biology and Endocrinology 2009, 7:49 http://www.rbej.com/content/7/1/49
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this at mid-gestation, TRPV6  expression was moderate
and then increased again at P13.5. From P12.5 to P21.5,
the expression of TRPV6 in the placenta steadily increased
and expressed at the highest level at P20.5 in rats (Figure
2).
Localization of TRPV6 protein in the uterus and placenta
The spatial distribution of TRPV6 protein in the rat uterus
and placenta was investigated by using an anti-TRPV6
antibody, respectively, when its transcripts were shown to
be expressed at relatively high levels. The rat uterus was
longitudinally sectioned. TRPV6 protein was detected on
the endometrial layer and glandular epithelium of the ges-
tating uterus. TRPV6 was observed on the glandular epi-
thelial apical layer but not on the basolateral membrane,
implying that this protein may control luminal calcium
ion transport (Figure 3). In addition, we observed that the
site of implantation was marked by swollen uterine tissue
(Figure 3). The site was strongly stained by anti-TRPV6
antibodies, supporting the notion that early embryo set-
tlement might require the expression of TRPV6 protein
(Figure 3). Between swollen areas in the rat uterus (Figure
3), TRPV6 was observed in the endometrial apical layer,
consistent with our previous reports [11,12].
TRPV6 protein was detected throughout the rat placenta
as seen in Figure 4. The placenta was separated from fetus
at P20.5 and the tissue was crossly sectioned. Three areas
were probed for TRPV6 expression: the inner and middle
labyrinth layers, and the spongy outer layer (Figure 4A, B
and 4C). Although the tissue layer on the embryo-
attached-side dominantly expressed TRPV6 protein, the
middle labyrinth area was also shown to express this pro-
tein. In the outer spongy layer containing giant cells,
TRPV6 immuno-positive cells were also detected as dem-
onstrated in Figure 4C.
In a time-dependent manner, uterine TRPV6 was mainly
detected in the epithelial and glandular cells of the non-
attached uteri of rats (Figure 5A). The TRPV6 positive cells
were observed on the attached uterus, while modest
TRPV6 signal was shown in the placental-like structure
regarded as the implantation site (Figure 5A). In addition,
TRPV6 positive cells were broadly observed through the
placenta containing the labyrinth and spongy zones in a
time-dependent manner (Figure 5B). The strong signals of
TRPV6 protein were detected on the fetal membranes as
shown.
Effects of sex steroid receptor antagonists on uterine and 
placental TRPV6 mRNA in a rat and mouse model
Recently, uterine TRPV6 was shown to be regulated by
progesterone in immature and non-pregnant rats [11],
whereas its expression in a mouse model was shown to be
controlled by estrogen [12]. To clarify which hormone
mediates uterine TRPV6  expression, the rats and mice
were treated with a single treatment of RU or ICI to invoke
progesterone and estrogen receptor antagonism condi-
tions, respectively. In the uterus at P5.5 (maximum
expression levels), RU treatment resulted in a significant
inhibition of TRPV6 mRNA expression in the rat uterus. In
addition, ICI significantly reduced TRPV6 transcription in
this tissue (Figure 6A). In the rat placenta, hormonal reg-
ulation was tested at P19.5 after a single treatment with
RU or ICI. Treatment with RU significantly down-regu-
lated the expression of placental TRPV6 at P20.5, while
ICI did not alter its expression in the rat placenta (Figure
6B), suggesting that placental TRPV6 transcription in ges-
tating rats may be controlled by progesterone and its
receptors.
Previously, we reported that uterine TRPV6 transcription
in mice was regulated by estrogen via estrogen receptor α
[12], but its placental regulation during pregnancy has not
been investigated. In the previous study, steroid hor-
mone-induced regulation of murine TRPV6 transcription
was shown by using ICI or RU at P10, a point in gestation
when  TRPV6  was previously reported to be highly
expressed [12]. As shown in Fig 6C, treatment with ICI sig-
nificantly reduced uterine TRPV6 expression, whereas RU
did not affect uterine TRPV6 transcription levels in the
mouse uterus. In addition, TRPV6 gene was significantly
down-regulated by ICI, while RU did not alter its mRNA
levels in the mouse placenta (Figure 6D). Taken together,
Placental TRPV6 mRNA expression during pregnancy in rats Figure 2
Placental TRPV6 mRNA expression during pregnancy 
in rats. Placentas were collected daily from P13.5 to P21.5. 
Placenta TRPV6 mRNA was examined by RT-PCR (Top panel, 
agarose gel image) and Real-Time PCR (Bottom panel, line 
graph). The line graph represents the analysis of Real-Time 
PCR data expressed as a percentage of TRPV6/HPRT1 (mean 
± SEM of duplicates).Reproductive Biology and Endocrinology 2009, 7:49 http://www.rbej.com/content/7/1/49
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these data indicate that uterine and placental TRPV6
expression may be primarily regulated by estrogen during
non-pregnancy and pregnancy in mice. This regulation of
TRPV6 expression by estrogen in mice is in contrast to
progesterone-mediated regulation in rats.
Discussion
Several uterine calcium-regulating genes are alternatively
expressed during estrous cycle and pregnancy [23]. In the
implantation period, calcium-binding proteins appear to
play a central role [8,12,24-33]. Calbindins are required
during the early phase of embryo implantation, implying
that the regulation of calcium availability in the vicinity of
the implanting embryo is critical for successful implanta-
tion [8,9]. Although the importance of calbindins in
implantation has been established, the precise role of cal-
cium ions during implantation remains unclear. Other
calcium processing genes have recently been identified in
female reproductive organs, and TRPV6 is an interesting
protein in elucidating uterine process of calcium
[11,12,34].
Uterine expression of TRPV6  varies during the estrous
cycle in rodents. For instance, rat TRPV6 transcripts in the
uterus were highly expressed at diestrus [11], while mouse
TRPV6 mRNA was highly expressed at estrus [12]. Distinct
their expression patterns indicate that uterine TRPV6 is
differentially regulated during the estrous cycle in rats and
mice. During pregnancy, mouse TRPV6 mRNA is actively
expressed with maximal expression observed in the mid-
dle of gestation, followed by a reduction in the late
period. Immediately prior to birth, another high level of
TRPV6 expression is observed, which disappears during
lactation [12]. In the present study, rat uterine TRPV6 was
modestly expressed at P0.5, which corroborates previous
reports; and this gene was up-regulated by progesterone at
Localization of uterine TRPV6 at P6.5 Figure 3
Localization of uterine TRPV6 at P6.5. Left panel, low power image of uterus showing representative TRPV6 immuno-
positive regions restricted to three histological areas (A – C) as spotted rectangles. A, glandular epithelium; B, putative implan-
tation site; C, epithelial layer. 'No first antibody' indicates immunoreactivity without anti-TRPV6 treatment, as a negative con-
trol. Arrows indicate immuno-positive staining.Reproductive Biology and Endocrinology 2009, 7:49 http://www.rbej.com/content/7/1/49
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the diestrous stage in a rat model [11]. In days after P0.5,
TRPV6 expression gradually decreased and was undetec-
ted at P4.5. However, at P5.5 a substantial increase and
peak in TRPV6 expression was observed. This time point
coincides with the earliest sign of the implantation attach-
ment reaction which occurs around P4 or P5 in rodents
[35]. Therefore, the maximal expression of TRPV6 gene at
P5.5 may be related to the regulation of uterine calcium
ion concentration required for successful implantation.
Calbindin-D9k, another uterine calcium associated pro-
tein, gradually increases at pregnancy day 16.5, peaks at
day 18.5, and declines at birth and the beginning of lacta-
tion [17]. A comparison of uterine TRPV6 and calbindin-
D9k time-dependent expressions in pregnant rats suggests
that these proteins may share in the function for main-
taining uterine calcium concentrations during pregnancy.
In mice, uterine calbindin-D9k showed a gradual increase
in mRNA expression during late pregnancy (from day
12.5 to 18.5), followed by a decline at birth and during
lactation [17]. It has also been reported that serum estro-
gen levels increase at the end of pregnancy and decline
sharply following birth and during lactation, whereas
serum progesterone levels remain constant throughout
late gestation and lactation [17]. With regard to these
studies, it is possible that increased serum estrogen levels
induce uterine TRPV6 transcription at birth and during
pregnancy, and that TRPV6 ceases during lactation when
secreted estrogen is no longer present. It was previously
shown that mouse TRPV6 expression in the placenta ini-
tially follows the pattern of uterine expression, with an
induction in the middle of gestation (P10.5 and P14.5)
but not at the end of gestation [12]. TRPV6 seems to have
a positive influence on transplacental calcium ion concen-
trations and to be a crucial factor in fetal development,
because it is highly expressed in human placenta as com-
pared to levels in other organs [36]. In the present study,
placental expression of TRPV6  gene steadily increased
from P12.5 to P20.5 before labor in rats. Taken together,
these results imply that constitutive expressions of TRPV6
and/or other calcium processing genes may play a crucial
role in transporting calcium ions from maternal to fetal
Localization of placental TRPV6 at P20.5 Figure 4
Localization of placental TRPV6 at P20.5. Left panel, overview of placenta divided into three distinct areas (A to C) 
showing TRPV6 immuno-staining as spotted rectangles. A, inner labyrinth area; B, middle labyrinth; C, spongy zone. 'No first 
antibody' indicates immunoreactivity without anti-TRPV6 treatment, as a negative control. Arrows indicate immuno-positive 
staining.Reproductive Biology and Endocrinology 2009, 7:49 http://www.rbej.com/content/7/1/49
Page 7 of 11
(page number not for citation purposes)
Spatial expression of uterine (A) and placental (B) TRPV6 expression in a time-dependent manner Figure 5
Spatial expression of uterine (A) and placental (B) TRPV6 expression in a time-dependent manner. A, Rat uteri 
from P5.5 to P10.5 were separately shown into the non-attached or attached uteri using anit-TRPV6 serum. u, attached uterus; 
f, placenta-like structure; arrows, epithelial and glandular cells. B, Rat placentas from P11.5 to P13.5 were presented in a time-
dependent manner. la, labyrinth zone; sp, spongy zone; gc, giant cells; arrows, fetal membrane.Reproductive Biology and Endocrinology 2009, 7:49 http://www.rbej.com/content/7/1/49
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Effects of steroid receptor antagonists on uterine and placental TRPV6 mRNA expressions Figure 6
Effects of steroid receptor antagonists on uterine and placental TRPV6 mRNA expressions. Panel A (uteri at P5.5) 
and B (placenta at P20.5) presented the rat TRPV6 mRNA levels. Four groups of pregnant rats (n = 4 per group) were treated 
with ethanol as a negative control (VE), progesterone receptor antagonist (RU, 2.5 mg per rat), or estrogen receptor antago-
nist (ICI, 0.5 mg per mouse). Panel C (uteri at P10.5) and D (placenta at P10.5) showed the mouse TRPV6 mRNA expressions. 
Four groups of pregnant mice (n = 4 per group) were treated with ethanol as a negative control (VE), progesterone receptor 
antagonist (RU, 25 μg per mouse) or estrogen receptor antagonist (ICI, 2 μg per mouse). Murine TRPV6 mRNA levels were 
examined by real-time PCR. The bar graph represents the analysis of real-time PCR data expressed as a percentage of TRPV6/
HPRT1 (mean ± SEM of duplicates). a, statistically significant compared to a vehicle (P < 0.05).Reproductive Biology and Endocrinology 2009, 7:49 http://www.rbej.com/content/7/1/49
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compartment during pregnancy. In addition, the changes
in the uterine transcript levels of TRPV6 as a function of
pregnancy may be largely a reflection of myometrial
changes in its expression in both rats and mice.
Rat TRPV6 protein was detected in the endometrial layer,
glandular epithelium and implantation site of the gestat-
ing uterus. This spatial pattern of TRPV6 expression
between uterus and placenta was previously demon-
strated [12]. In parallel with TRPV6, rodent calbindin-D9k
was detected predominantly in luminal epithelial cells of
the uterus of pregnant rats [17,37]. The similar spatial dis-
tribution of these gene products further supports the con-
cept of a complementary function for TRPV6 and
calbindin-D9k in the control of calcium ions during preg-
nancy. In rodent models, placental localization of TRPV6
protein in the labyrinth and spongy zone implies that this
protein may take part in transporting calcium ions
between fetus and dam. In regard to its expression levels
during pregnancy, the expression of TRPV6 protein would
be highest in the myometrium as shown in this study.
Progesterone has been implicated as a major regulator in
the expression of TRPV6 during the rat estrous cycle [11].
The progesterone receptor antagonist (RU) significantly
blocked progesterone-induced TRPV6 gene transcription
[11]. The expression of uterine TRPV6 mRNA at P5.5 was
completely inhibited by RU treatment, and partially
inhibited by treatments with ICI. Partial inhibition of
TRPV6 expression by ICI may be attributed to the action
of estrogen receptor at estrogen response elements (EREs)
found in the promoter region of the progesterone receptor
gene. Although ICI partially down-regulated TRPV6 gene
in the rat uterus, progesterone and its receptor appear to
primarily control uterine TRPV6 transcripts in this tissue
during pregnancy.
A recent study provides the first in vivo evidence that
TRPV6 is involved in maternal-fetal Ca2+ transport, pro-
posing that TRPV6 functions as a Ca2+ entry pathway,
which is critical for fetal Ca2+ homeostasis [16]. In addi-
tion, a phenotype of mice with targeted disruption of
TRPV6 gene was reported. TRPV6 knockout (KO) mice
showed disordered Ca2+ homeostasis and reduced fertil-
ity, and deficient maternal-fetal transfer of calcium ions
caused abnormal calcium ion deficiency during embry-
onic development [38]. In this study, placental TRPV6
expression is expected to enhance the rate of maternal
transfer of calcium ions to the fetus during pregnancy
[38]. In the present study, the expression of placental
TRPV6 mRNA in rats was blocked by RU treatment, but no
significant inhibitory effect was observed for ICI treat-
ments, suggesting that placental TRPV6  expression is
under the sole control of progesterone via a progesterone
receptor-mediated pathway. However we cannot rule out
the possibility that the difference in their doses may
account for the observed difference between rats and
mice.
In contrast to rats, it was previously reported that murine
uterine TRPV6 transcription at normal estrous cycles was
totally dependent on estrogen [12]. Uterine TRPV6 mRNA
levels increased at mid and late pregnancy, and were
strongly induced at mid-pregnancy in the labyrinth and
spongy zones of the placenta, and in the fetal membrane
[12]. To examine an expression pattern of TRPV6 tran-
scripts by steroids compared to its level in rats during
pregnancy, we treated the mice with steroids, E2 and P4,
and isolated the identical tissues from them to measure
TRPV6 levels. In the present study, sex steroids controlled
uterine and placental TRPV6  expression during preg-
nancy. The expression of uterine TRPV6 mRNA at P10 was
blocked by ICI, and placental TRPV6 transcription was
blocked by ICI, suggesting that the expression of TRPV6
was primarily regulated by estrogen in gestating uteri and
placenta during pregnancy in mice. These results suggest
that TRPV6 may be distinctly regulated by different sex
steroids, progesterone in rats and estrogen in mice, in
spite of shared similarities in their chromosomal make-up
[12,20,39].
These results show that uterine and placental TRPV6
mRNA levels in rats appear to cyclically change during
pregnancy, suggesting that TRPV6 protein may participate
in the implantation process. It was of interest to note that
uterine TRPV6 mRNA is only expressed in placenta-unat-
tached areas of the uterus, indicating that TRPV6 has at
least two functions: implantation of the embryo and
maintenance of pregnancy. In rats, TRPV6 transcription
appeared to be solely controlled by P4 through PRs, while
its level was regulated by E2 via ERs in mice. In both
rodents, uterine TRPV6 immunoreactivity was observed in
luminal and glandular epithelial cells, and in the placenta
TRPV6 was detected in the labyrinth and spongy zone.
The juxtaposition of uterine and placental TRPV6
expressed in these tissues can support a novel concept that
TRPV6 participates in transporting calcium ions between
the maternal and fetal compartments. In conclusion,
TRPV6 gene may function as a key element in controlling
calcium transport in the uterus between the embryo and
the placenta during pregnancy.
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